Testing Status of Salicylazosulfapyridine 11177-H
CASRN: 599-79-1
Formula: C18-H14-N4-O5-S
Synonyms/Common Names
- 2-Hydroxy-5-((4-((2-pyridinylamino)sulfonyl)phenyl)azobenzoic acid (9CI)
- SASP
- Sulfasalazine
Short-Term Toxicity
- 14-Day (Gavage)
(C61552)
Completed
- Rats: F344/N; Mice: B6C3F1
- 13 weeks (Gavage)
(C61552)
Completed
- Rats: F344/N; Mice: B6C3F1
- Dose: R: 0, 84, 169, OR 337 M: 0, 675, 1350, OR 2700 MG/KG.
Long-Term Carcinogenicity
- 2 & 3 years (Gavage)
(C61552B)
Completed
- TR-457 (NIH Number: 97-3373)
(Peer Review Approval 06/20/1995A )
Toxicology and Carcinogenesis Studies of Salicylazosulfapyridine (CASRN 599-79-1) in F344 Rats and B6C3F1 Mice (Gavage Studies) - Rats: F344/N; Mice: B6C3F1
- Dose: R: 84, 168, OR 337.5 MG/KG; 70/GROUP M: 675, 1350, OR 2700 MG/KG; 60/GROUP.
- Carcinogenesis Results
- Male Rats Some Evidence
- Female Rats Some Evidence
- Male Mice Clear Evidence
- Female Mice Clear Evidence
- TR-457 (NIH Number: 97-3373)
(Peer Review Approval 06/20/1995A )
Special Studies
- Toxicokinetic Study (Gavage; Intravenous; Gavage; Intravenous)
(S0312)
Completed
- Citation: Zheng W, Winter SM, Mayersohn M, Bishop JB, Sipes IG. Toxicokinetics of sulfasalazine (salicylazosulfapyridine) and its metabolites in B6C3F1 mice. Drug Metab Dispos. 1993 Nov-Dec;21(6):1091-7.Pubmed Abstract
- Male Rats [R]: F344/N; Male and Female Mice [M]: B6C3F1
- Dose: (gavage) 67.5, 675 mg/kg [R]. (intravenous) 5 mg/kg [R,M]. (gavage) 67.5, 675, 1350, 2700 mg/kg (single dose); 675, 1350, 2700 mg/kg/day (3-day repeat dose) [M].
Genetic Toxicology
- Chromosome Aberrations
(459882)
Completed
- Citation: Bishop JB, Witt KL, Gulati DK, MacGregor JT. Evaluation of the mutagenicity of the anti-inflammatory drug salicylazosulfapyridine (SASP). Mutagenesis. 1990 Nov;5(6):549-54. doi: 10.1093/mutage/5.6.549
- Mice
- Negative (Nonstandard Protocol)
- Chromosome Aberrations
(724355)
Completed
- Mice
- Negative (Nonstandard Protocol)
- Chromosome Aberrations
(A93691)
Completed
- Mice
- Negative (Nonstandard Protocol)
- In Vitro Cytogenetics (CA/SCE)
(291257)
Completed
- Citation: Bishop JB, Witt KL, Gulati DK, MacGregor JT. Evaluation of the mutagenicity of the anti-inflammatory drug salicylazosulfapyridine (SASP). Mutagenesis. 1990 Nov;5(6):549-54. doi: 10.1093/mutage/5.6.549
- Sister Chromatid Exchange Negative
- Chromosome Aberrations Negative
- Micronucleus
(107236)
Completed
- Rats: Fischer 344
- Male Equivocal
- Micronucleus
(459882)
Completed
- Citation: Bishop JB, Witt KL, Gulati DK, MacGregor JT. Evaluation of the mutagenicity of the anti-inflammatory drug salicylazosulfapyridine (SASP). Mutagenesis. 1990 Nov;5(6):549-54. doi: 10.1093/mutage/5.6.549
- Mice: B6C3F1
- Male Negative
- Micronucleus
(724355)
Completed
- Mice: B6C3F1
- Male Not a Valid Test
- Micronucleus
(A66124)
Completed
- Citation: Bishop JB, Witt KL, Gulati DK, MacGregor JT. Evaluation of the mutagenicity of the anti-inflammatory drug salicylazosulfapyridine (SASP). Mutagenesis. 1990 Nov;5(6):549-54. doi: 10.1093/mutage/5.6.549
- Citation: Witt KL, Knapton A, Wehr CM, Hook GJ, Mirsalis J, Shelby MD, MacGregor JT. Micronucleated erythrocyte frequency in peripheral blood of B6C3F(1) mice from short-term, prechronic, and chronic studies of the NTP carcinogenesis bioassay program. Environ Mol Mutagen. 2000;36(3):163-94
- Mice: B6C3F1
- Male Positive
- Female Positive
- Micronucleus
(A72306)
Completed
- Mice: B6C3F1
- Male Positive
- Micronucleus
(A93691)
Completed
- Mice: B6C3F1
- Male Positive (Nonstandard Protocol)
- Female Positive
- Salmonella
(031562)
Completed
- Citation: Zeiger E, Anderson B, Haworth S, Lawlor T, Mortelmans K. Salmonella mutagenicity tests: IV. Results from the testing of 300 chemicals. Environ Mol Mutagen. 1988;11 Suppl 12:1-157
- Negative
- Sister Chromatid Exchanges
(724355)
Completed
- Mice
- Sister Chromatid Negative (Nonstandard Protocol)
Organ Systems Toxicity
- greater than 120 days Continuous Breeding (Legacy) (Gavage)
(RACB90002)
Completed
- Rats: Sprague Dawley
- Dose: 0, 100, 200, 400, 600, 800 MG/KG; 0, 100, 200, 400 MG/KG/DAY; 0, 100, 200, 400 MG/KG/DAY; 0, 100, 200, 400 MG/KG/DAY.